key: cord-1054141-al539qoc authors: Sharma, Sparsh title: The debate around the access to vaccine and licensing amidst second wave of COVID‐19 in India date: 2021-08-02 journal: J World Intellect Prop DOI: 10.1111/jwip.12195 sha: c3dbe341d0011d342ac7f29e58da30a4763d054e doc_id: 1054141 cord_uid: al539qoc The guardian of global health signified a “global response” to contain COVID 19 utilising the platform of World Health Organization when the novel virus strain was spreading. The nature of “waves,” that is, variable epidemiological patterns and peaks in trajectory, have been inconsistent and myriad in different regions and countries. Many researchers and scholars have deliberated on the possible ways forward to curb or mitigate the effects of the virus; and one such means is through universal vaccination. Hence, this article explores the positions to achieve that goal by looking at the licensing aspect and IP waiver debate and suggests a fine‐tuning which balances all the interests, amidst the second wave in India. syndrome and mucormycosis (commonly called "black fungus") which has a starking mortality rate of 50% (Biswas, 2021) . Therefore, it calls for an overhaul of the whole process aimed to expedite production and make vaccines more accessible. Vaccines, unlike conventional drugs, require the highest standards of quality, efficacy and safety for satisfying the regulatory framework. The framework ensures that its benefits outweigh the risks (or side effects) in dealing with deadly infections like COVID-19 (WHO, 2021a). The UN in 2015 formulated 17 Sustainable Development Goals (SDGs) under 2030 Agenda. COVID-19 falls within the 3rd SDG which deals with the health of people (UN SDGs, 2020) . Further, the UN adopted "Comprehensive and coordinated response to the coronavirus disease (COVID-19) pandemic" and "United response against global health threats: combating COVID-19" (GA/12262), acknowleding the pandemic as a global concern and calling for collaborative efforts to deal with the virus (United Nations, 2020). The ongoing 74th World Health Assembly (WHO, 2021e) has again highlighted equitable access to vaccines, especially to health and care workers like the previous 73rd World Health Assembly Resolution on "COVID-19 response," vide WHA 73.1. The WHO assesses and evaluates the efficacy of the vaccine to combat COVID-19 outbreak from the global perspective while granting Emergency Use Listing (EUL). EUL is an exceptional mechanism invoked by WHO in public health emergencies where candidates propose their Expression of Interest before WHO for approval of an investigational vaccine. The process is fast-tracked on the principle of larger benefit to the target population that outweighs the risk of its use to make the vaccine more accessible. The respective National Regulatory Authorities (NRAs) aid WHO in assessment of the vaccine candidate. As yet, six candidates are approved under EUL (Table 1 ). In India, nationwide vaccination drive was rolled out on January 16, 2021 (BusinessToday.In, 2021) after approval of two vaccine candidates on January 3, 2021 which need to be administered in two doses. 2 First, Serum Institute of India, Pune, vaccine candidate "Covishield" (recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2) is a license and technology transfer from AstraZeneca/Oxford University candidate (AZD1222). Second, "Covaxin" (whole virion inactivated coronavirus Vaccine) is an indigenously manufactured candidate by Bharat Biotech International Ltd. in collaboration with ICMR and NIV (Pune). Notwithstanding the candidate not yet getting the EUL seal of the WHO, it is being used for inoculation in India and some other countries. However, the GoI aims to push for the same before WHO to instill confidence among people and other countries which are a bit sceptical (Parashar, 2021 A VL, simply put, refers to a private contractual arrangement between IP holders and the manufacturers to develop a generic version of medicine in which the patent subsists. The idea behind this is that it is generally accompanied by the transfer of know-how 4 by the licensor to the licensee as per the royalty/premium decided at the time of execution of the license. It may be a nonexclusive arrangement where such license rights are transferred to multiple players in the form of a patent pool. Case study-Remdesivir, meant to treat Ebola virus was suggested to be effective against the current COVID-19 also-it dealt with a method for treating Arenaviridae and coronaviridae virus infection (Sheahanan et al., 2020) . The parent Co. of the drug provided nonexclusive voluntary licensing agreements to generic manufacturers like Cipla Ltd., Dr. Reddy's Laboratories Ltd., Eva Pharma, Ferozsons Laboratories, and so forth, which covered as many as 127 countries including India and Pakistan (Gilead, 2021) . The cost factor also reduced due to this in developing countries because of generic players. However the drawback in this arrangement is the "voluntariness." The IP holder holds discretion in terms of allocating licenses and undoubtedly profit making is the driving force for such negotiations to mature. FICCI said in a recent statement "facilitate technology transfer and VLs to Indian companies that have the capacity and capability for massproduction of COVID vaccines" (Saluja, 2021) . But this, albeit ideal scenario, is a weak obligation on part of the IP holder without any bindingness further supplemented by the fact that licensees compete against each other and it is unlikely that a generic from a developing country can overpass the one from the advanced nations. Many had prebooked supplies and contracted for the licence through internal mechanisms much earlier at the development stage. CLs, on the other hand, permit generic manufacturers to produce what can be called "copycat versions" of patented drugs which can be sold at much cheaper rates as compared to the patented drug in the event of In India, Bayer v Natco 5 was the only instance of grant of CL in favour of Natco (generic Co.) with respect to the drug sorafenib tosylate (anticancer drug) on ground of nonworking of the patent, that is, less availability (Bonadio, 2012) . More recently, Natco, has yet again filed a CL request under Section 92 6 for "Baricitinib" (used for treatment of COVID-19) citing public needs, essentially the affordability and the access. Notwithstanding the fact that CL brought down the price of the drug (after Bayer v Natco 7 ), Natco was capable enough to know the "technology" behind the drug which is not the case with vaccines as they are complex trade secrets especially in light of COVID-19 (O'Sullivan et al., 2021) . Therefore invoking the provision only "for the sake" would do no good under the myth of "enhanced production" but instead harm innovation. Two essentials for success of CL (Hilty et al., 2021) : 1. Aactual manufacturing capacity and facilities Even if India satisfies point 1 it perhaps falls short on 2. As it is not a simple small-molecule drug or traditional vaccines but messenger RNA (mRNA)-based candidate which pose bigger challenges (Stolberg, 2021) . Further, political and internal calculations are involved in CL as it is a domestic call of respective govt. Therefore, given the position of India on the WTO forum for IP waiver, invoking CL would weaken the case of shortage and stifle drug manufacturers to negotiate voluntarily with IP holders abroad in future. This is due to determination of "fairness" of license fee which is comparatively low as the ultimate discretion lies with the domestic courts. Therefore two schools of thoughts primarily emerge-one, which considers IP as an impediment/wall blocking the ability of countries to rapidly procure and produce; and second, which backs the exclusive IP rights granted to the inventors for the progress of science. The author believes that mere presence of a provision of IP waiver in TRIPS does not mean that invoking it ought to be beneficial much like the CL (drawing an analogy, just because you have yogic flexibility does not mean you over-stretch lest it 6 | SHARMA may even cause injury). It is not justified and ethical to punish all innovators (IP holders) by threatening their investment for the wrongdoings of a few, who refuse licensing on "objective grounds" as such refusals are only exceptional (Hilty et al., 2021) . Notwithstanding Moderna's vaccine patent, it pledged not to enforce the same (Shores, 2020) . However, roughly after 6 months, it's CEO Stéphane Bancel indicated in a conference that the waiver had nothing to do with the mRNA vaccine's access, as "people don't know how to make it" (Jimenez, 2021) . This is in addition to repercussions which might occur if the IP holder/manufacturer reduces its own self-production. This directly conveys the message that if IP is waived, the holders would be reluctant to give marketing authorisation licence, that is, in terms of providing the safety and quality standards and sharing required data and know-how (Hilty et al., 2021) . Therefore, the delay is imminent as the generics would have to de novo prove 2 things-first, the similarity with the reference vaccine candidate; second, rule out the differences (clinically) on counts of safety and efficacy. Lastly, the disincentive effect would writ large in the minds of innovators and operate as a dangerous precedent for the future. As many vaccines were actually researched and developed before, not initially intended for Effective and efficient supply chain is key to control the virus. This includes logistics, raw materials supply (upstream, downstream) , local storages, other/ancillary supplies, ImpEx flexibility, removal of export restrictions, and so forth, under COVID-19 exemptions and levy. The more lubricated and well-managed the setup is, the better will be the production capabilities. This is attributed to "scaling up" and "speeding up" of the entire machinery which ultimately will shoot up the supply to meet the demand curve. It is not just essential, but need of the hour, because unlike other policy reforms for vaccine equitability, this can be implemented as soon as possible to mitigate the SHARMA | 7 deaths and cases and address challenges in the short-run, till a decision or consensus is reached wrt patent waiver or other suggested route. Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations had also remarked these as "bottlenecks" (to "The Lancet"), created due to inefficient-"sourcing of scarce ingredients, trained technicians, necessary stringent quality checks, as well as other logistic and regulatory challenges (Zarocostas, 2021) ." Last but not the least, today, transboundary companies or ventures are very common due to multilateralism and inter-connectedness. Fisher et al. (2021) gives examples of the Government of Uganda's National Drug Policy, 2002 , and National Strategic Plan (2007 -2012 to locally produce drugs to tackle AIDS; similarly Ethiopia's "Health Sector Development Plan" (partnered with the WHO); and Pharmaceutical Manufacturing Plan for Africa in 2008all intended to revive local manufacturing of drugs by providing technical assistance, business linkage, Good Manufacturing Practice (GMP) and sustainability via strategic partnerships. The idea here is that the external player possesses the same object as that of the local player. The profit/equity shares can be allocated and decided in the agreement. Thus, this objective can be achieved by "tactical alliance" or "Joint venture-JV" (a kind of "strategic partnership" with the local player). The IP holder can then provide the adequate technology transfer and utilise local player's production capabilities. Cipla Pharmaceuticals-Quality Chemicals JV is therefore a template where even the government of Uganda possessed a stake in the first plant. Such an arrangement is referred to as "production triangle" as it involves three primary players in developing a world-class facility (Fisher et al., 2021) . In is also in alignment with GoI's "Vocal For Local" campaign. The idea is also in sync with the "third way," as suggested by Okonjo-Iweala (Director General-WTO), referring to equitable technology transfer that is ensured within the multilateral framework and commitment (Zarocostas, 2021) . Dr. Reddy's Laboratories-Gamaleya Research Institute of Epidemiology and Microbiology tie-up for Sputnik V vaccine is a step in this direction (the production triangle), but the GoI needs to get proactively involved not just as a facilitator but also as a purchaser of the stocks/stakes for a designated locking period (a formula between the central and state govt. for purchases may be designed) to encourage such investments in future as it plans to administer doses free of cost/subsidised rates. These proposals without hampering innovation in the long run (the fact that COVID-19 is not the last such virulent disease), address access to healthcare via alternate means in a quick manner and perhaps entail lesser time for enforcement. Whereas IP waivers or CLs possess drawbacks and need global consensus or face local challenges which need time for enforcement. Ricardian law of comparative advantage, in simple terms highlights the notion of-do what you are good at. In international trade, there exists no uniform production and in a world with diversified specialization, reward based technical transfer ought to entail minimum social cost and do overall public good. This is because, in such tie-ups, 8 | SHARMA the vaccine need not be reverse engineered (time, infra wastage due to resource misutilization) due to lack of knowhow. India's generic manufacturing capability needs to be utilised for its own as well as overall global good (WION Web, 2021) . The extremist views either calling for a waiver/CL or a vaccine nationalism are both harmful (to be utilised onlyif all "other possible ways" are exhausted). Instead a synthesis between the two approaches (a hybrid model) which increases "voluntariness" of the IP holder to enter into a contract should be looked upon, as suggested from the discussions above. It is a win-win arrangement for all stakeholders as it results in-scale up, speed up, better marketing/advertisement, IP holders' interest fulfilling altruistic justifications of IP (Bonadio & Baldini, 2020) to establish favourable conditions for collaboration, exchange and for speeding up the process of scientific discovery. Such a cocktail of best practices from all available flexibilities can be a tailor made approach, acceptable to all, would strengthen Global Health Security (Assefa et al., 2020) and would act as a better precedent for future outbreaks. It would therefore balance relative opportunity costs of countries and companies towards an equitable and rewards based lucrative setup. The authors declare that there are no conflict of interests. This article was written before May 2021 and the situation prevailing at that point in time. The facts and figures might have changed with passage of time when this article is accepted for publication. The author has declared that no competing interests exist that have influenced the text and this piece is his unbiased opinion. The data that support the findings of this study are available from the corresponding author upon reasonable request. means, methods, processes, pracces, formulae, instrucons, skills, techniques, procedures, experiences, ideas, designs, drawings, assembly procedures, soware, computer programs, apparatuses, specifications, data, results and materials, including: biological, chemical, vaccine-related, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety , manufacturing and quality control data and information, including study designs and protocols, assays, and biological methodology, in all cases, whether or not copyrightable or patentable, in wrien, electronic or any other form now known or hereafter developed," quoted from Lonza Ltd. Sparsh Sharma http://orcid.org/0000-0002-9262-9839 Global health security and universal health coverage: Understanding convergences and divergences for a synergistic response Black fungus: India reports nearly 9,000 cases of rare infection Compulsory licensing of patents: The Bayer-Natco case COVID-19, patents and the never-ending tension between proprietary rights and the protection of public health COVID-19 vaccination drive in India to begin on Third COVID wave "inevitable": K Vijay Raghavan, principal scientific advisor to Central Govt Fostering @@production of pharmaceutical products in developing countries Voluntary licensing agreements for remdesivir The COVID-19 pandemic and international trade: Temporary turbulence or paradigm shift? COVAX joint statement: Call to action to equip COVAX to deliver 2 billion doses in 2021 COVID-19 and the role of intellectual property: Position statement of the Max Planck Institute for innovation and competition of 7 COVID-19: B.1.617 variant which originated in India found in 65% of samples sequenced, says health minister COVID-19 vaccine inequity: The debate over patent waivers intensifies Daily new confirmed COVID-19 cases Global long term agreement Patents. Retrieved Why tech transfer may be critical to beating COVID-19 Government steps in to expedite WHO approval for Covaxin Coronavirus pandemic (COVID-19)-Statistics and research Focus on technology transfer, voluntary licenses to Indian companies to address vaccine shortage: FICCI Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Breaking down Moderna's COVID-19 patent pledge: Why did they do it? Emergent BioSolutions halts operations at its Baltimore plant, where J.&J. doses were ruined Intellectual property, innovation and access to health products for COVID-19: A review of measures taken by different countries General assembly adopts omnibus resolution calling for holistic COVID-19 response, among 3 passed on global health threats, malaria | Meetings coverage and press releases Update from the seventy-fourth World Health Assembly-28 Solidarity call to action UN chief praises Indian vaccine making capacity, calls it an asset Waiver from certain provisions of the TRIPS agreement for the prevention, containment and treatment of COVID-19 New WTO leader faces COVID-19 challenges